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ABSTRACT 
Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) is a new synthetic 
inhibitor of matrix metalloproteinases (MMPs) with a high selectivity towards MMP2, MMP9 and membrane 
type 1-MMP. It has been shown that cyclodextrins (CDs) are able to form inclusion complexes with Ro 28-2653 
and to increase its aqueous solubility. The aim of this study is to demonstrate that an increase in Ro 28-2653 
solubility, via ternary complex formation, can lead to an increase in the oral bioavailability of this drug.                
This study shows that a synergistic effect exists between hydroxypropyl-β-cyclodextrin (HP-β-CD) and L-lysine. 
The use of this multicomponent system enabled the preparation of oral and intravenous solutions of Ro 28-2653. 
In vivo evaluation of the oral solution of the inclusion complex of Ro 28-2653 in comparison with a suspension 
of the same uncomplexed drug showed a significant (p < 0.05) increase in absolute bioavailability. The area 
undercurve (AUC) and the peak serum concentration (Cmax) were approximately 10 times higher than those 
obtained with the suspension, while the time (Tmax) to reach Cmax was reduced. Moreover, in vivo administration 
of Ro 28-2653 solutions highlighted some information about the pharmacokinetic behavior of Ro 28-2653: a 
long biologic half-life (about 15.5 h) and a small overall volume of distribution (81). 
1. Introduction 
Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-l-yl]-pyrimidine-2,4,6-trione) (Fig. 1) is a new 
synthetic inhibitor of matrix metalloproteinases (MMPs) (Grams et al., 2001; Lein et al, 2002; Mangoldt et al., 
2002; Noel et al., 2000; Opalka et al., 2002). These enzymes have recently become important in the field of 
anticancer drug research: they play a crucial and complex role in tumor growth, angiogenesis and formation of 
metastasis (Egeblad and Werb, 2002; Fingleton, 2003; Overall and Lopez-Otin, 2002; Vihinen and Kahari, 
2002). Among the inhibitors of MMPs recently synthesized, Ro 28-2653 presents a high selectivity towards 
MMP2, MMP9 and membrane type 1-MMP (Grams et al, 2001; Lein et al, 2002; Noel et al., 2000; Opalka et al., 
2002). These three MMPs seem to play a major role in tumor development and aggressiveness (Itoh et al., 1998, 
1999; Mangoldt et al., 2002; Noel et al., 2004; Sounni et al., 2003; Talvensaari-Mattila et al., 1998). This 
selectivity may be of interest with regard to increasing efficacy of the drug and to decreasing side effects mainly 
reported from other MMPs inhibitors, such as musculoskeletal pain (Arlt et al., 2002; Fingleton, 2003; 
Taraboletti and Margosio, 2001). It has been shown that this promising compound is able to reduce tumor 
growth in orthotopic prostatic cancer in rats; a significantly prolonged survival of the treated rats was also 
demonstrated (Lein et al., 2002). In addition, high efficacy in several types of cancer in in vivo models and 
regarding the drug's antiangiogenic effects have been reported (Noel et al., 2000). 
Unfortunately, Ro 28-2653 is a drug that exhibits poor water-solubility. This low solubility (about 0.56 µg/ml in 
water at 25°C) makes the pharmaceutical formulation of oral or injectable solutions difficult and reduces 
flexibility in terms of administration (Bertholet et al., 2005). Furthermore, the lack of aqueous solubility may 
lead to poor and erratic absorption from the gastrointestinal tract and, consequently, low and variable 
bioavailability may occur. In order to overcome these drawbacks, increasing the aqueous solubility of Ro 28-
2653 is an important goal. 
Cyclodextrins (CDs) are cyclic oligosaccharides used in pharmaceutical formulations to enhance solubility, 
dissolution rate and stability of compounds showing poor water-solubility These changes are caused by 
complexation of hydrophobic drug molecules or hydrophobic parts of drugs into their apolar cavity (Loftsson 
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and Brewster, 1996; Mosher and Thompson, 2000). Furthermore, in oral drug delivery, CDs can modify the 
absorption of drugs, thus increasing the bioavailability of active compounds with poor water-solubility 
(Rajewski and Stella, 1996). 
Fig. 1 - Chemical structure of Ro 28-2653. 
 
Several CDs have been considered for their ability to form inclusion complexes with Ro 28-2653 (Bertholet et 
al., 2005). Among these cyclodextrins, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) appears to be especially 
useful, based on its safety for intravenous administration and on its complexation potential (Bertholet et al., 
2005; Brewster and Loftsson, 2002; Irie and Uekama, 1997; Ma et al., 1999; Mosher and Thompson, 2000). 
Previous studies have already reported a combined effect of CDs and acid or alkaline compounds on the 
solubility of alkaline or acidic lipophilic drugs, respectively: complexation and simultaneous salt formation 
allow higher solubility in comparison with simple binary complexes (Redenti et al., 2000, 2001). In some cases, 
this result is reflected in higher bioavailability (rate and extent of absorption) (Redenti et al., 2001). Aminoacids, 
such as L-lysine, are often employed to increase the complexation efficiency of CDs with acidic compounds 
such as Ro 28-2653 (pyrimidine-2,4,6-trione) (Mura et al., 2003; Piel et al., 1997; Redenti et al., 2001). 
The objective of this study is to demonstrate that an increase in Ro 28-2653 solubility, via ternary complex 
formation, can lead to an increase in the oral bioavailability of this drug. Firstly, the solubilizing efficiency of a 
combination of HP-β-CD and L-lysine is studied in order to formulate a parenteral and an oral solution of Ro 28-
2653. Secondly, the pharmacokinetic parameters of Ro 28-2653 are determined after intravenous administration 
in sheep and in vivo data of the solution, containing the inclusion complex of Ro 28-2653, are compared to those 
of an aqueous suspension after oral administration. 
2. Materials and methods 
2.1. Drug and products 
Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) was synthesized by 
SYNTHEVAL (Caen, France). HP-β-CD (Kleptose® HPB, D.S. = 0.64, Eur. Ph. 4th ed.) was kindly given by 
Roquette (Lestrem, France). A pyrogen-free grade was used for preparing the intravenous solution. L-lysine was 
supplied by Fluka (Buchs, Switzerland) and water for injection (Viaflo®) by Baxter (Lessines, Belgium). All 
other products were of analytical or HPLC grade. 
2.2. Solubility studies 
Solubility studies were performed as described by Higuchi and Connors (Higuchi and Connors, 1965). Excess 
amounts of Ro 28-2653 were added to increasing concentrations of HP-β-CD (0-200 mM) in 5 ml dissolution 
media, either purified water or L-lysine solutions (50 or 500 mM). The glass containers were sealed and the 
suspensions shaken in a water-bath at 25 °C until complexation equilibrium was reached (7 days). An aliquot 
was filtered through a 0.45 µm PVDF membrane filter and assayed for Ro 28-2653 content by a validated liquid 
chromatography (LC) method (Bertholet et al., 2005). The pH values of the different solutions were recorded at 
complexation equilibrium. 
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2.3. Dosage form preparations 
The Ro 28-2653/HP-β-CD intravenous solution was obtained by dissolving Ro 28-2653 (10mg/ml) in a solution 
containing HP-β-CD (200 mM), L-lysine (20 mM) and water for injection. 
The osmolality (about 325 mOsmol/kg) and the pH (about 8.2) values of this solution are compatible with an 
intravenous injection. The solution was sterilized by being passed through a sterile 0.20 µm cellulose acetate 
filter under aseptic conditions. 
The Ro 28-2653/HP-β-CD oral solution was prepared by dissolving Ro 28-2653 (15mg/ml) in a solution 
containing HP-β-CD (200 mM), L-lysine (50 mM) and water. The pH value of this solution was about 9.0. 
The Ro 28-2653 suspension was composed of Ro 28-2653 (15mg/ml), with polysorbate 80 (0.1mg/ml) as a 
wetting agent, together with simaldrate (VEEGUM HV®, 1% m/v) and methylcellulose (METHOCEL A400®, 
0.4% m/v) as viscosifying agents. 
2.4. Animal experimental protocol and drug administration 
Six healthy sheep (two males and four females) ranging from 45 to 82 kg of body weight were used as 
experimental animals. Sheep were chosen for this preliminary study because of the easiness of both intravenous 
and oral administration with this species and because of their availability. During the test, the animals were fed 
and watered ad libitum. The experimental study, which was realized following the scheme of Table 1, included a 
randomized two-way cross-over design for oral administration followed by intravenous administration. A wash-
out period of 3 weeks was allowed between each administration. 
For the oral dosage forms, each animal received an Ro 28-2653 dose equal to 15 mg/kg of body weight from 
both formulations. Sheep were weighed on the day of drug administration in order to adapt the dosage form 
volume. Blood samples were taken from jugular vein before oral administration and at intervals of 0.25, 
0.5,1,1.5, 2, 3, 4, 6, 8,10, 12, 24, 28, 32, 48, 72, 96,120,144,168h afterwards. 
For the intravenous dosage form, all six sheep received 5 mg of Ro 28-2653/kg of body weight. The solution was 
administered through the left jugular vein. Blood samples were taken from the right jugular vein before 
intravenous administration and at intervals of 5,10,15, 20, 30, 45 min, 1,1.5, 2, 3, 4, 5, 6, 8, 10,12, 24, 28, 32, 48, 
72, 96, 120, 144,168h afterwards. All blood samples were centrifuged and the serums were stored at -80 °C until 
assayed. 
This animal experimental study was undertaken at the 'Centre d'Economie Rurale' (Marloie, Belgium) and had 
been approved by its own ethics committee. 
 
Table 1 - Animal experimental design for administration of solutions and suspension containing Ro 28-2653 
Sheep 1st Phase 2nd Phase 3rd Phase 
1 Oral suspension Oral solution IV Solution 
2 Oral suspension Oral solution IV Solution 
3 Oral suspension Oral solution IV Solution 
4 Oral solution Oral suspension IV Solution 
5 Oral solution Oral suspension IV Solution 
6 Oral solution Oral suspension IV Solution 
 
2.5. Bioαnαlysis method 
A fully automated method was developed for the LC determination of this compound in serum. Sample clean-up 
was performed by on-line coupling of a pre-column packed with restricted access material (RAM), namely 
LiChrospher RP-8 ADS (alkyl diol silica), with the analytical column by means of the column-switching 
technique. The ADS sorbents belong to the group of internal surface reversed-phase supports and have been 
applied successfully to the clean-up of biological samples prior to LC analysis (Hubert et al., 1999a; Souverain et 
al., 2004; Yu and Westerlund, 1997). The operating conditions are described in a previous paper (Chiap et al., 
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2005). The method was fully validated according to a novel approach based on accuracy profiles, taking into 
account the total measurement error (Hubert et al, 1999b, 2003, 2004). 
For the bioanalytical study, the dosing range of the method had to be increased to 50 µg/ml due to the high 
concentrations needing to be determined. A partial revalidation was performed and good results were obtained 
with respect to response function, trueness, precision, accuracy and linearity. 
2.6. Pharmacokinetics and statistical analysis 
For the intravenous administration study, the pharmacokinetic parameters were determined for each animal using 
a linear two-compartment model with first-order distribution and elimination (Boroujerdi, 2002). The areas 
under the curve values (AUCs0-168) were calculated by linear trapezoidal rule during the sampling period. The 
following were calculated using conventional equations associated with compartmental analysis: the AUC 
extrapolated until infinite values (AUCs0-∞), the total body clearance values (Clt), the biologic half-life (T1/2β) and 
the overall volume of distribution (Vdt) (Boroujerdi, 2002). 
For the oral administration study, the pharmacokinetic parameters were determined, for each animal and for both 
suspension and solution, using a linear one-compartment model with first-order input and first-order output 
(Boroujerdi, 2002). The AUCs0-168 were calculated as described above by trapezoidal summation. The AUCs0-∞ 
were estimated by the following equation (Eq. (1)): 
 
Where K and Ka are, respectively, overall elimination rate constant and absorption rate constant, and C0 is the 
extrapolated concentration at origin. 
The maximum concentrations of drug in plasma (Cmax) and the corresponding times (Tmax) were determined for 
each animal by two different means: directly from the concentration-time graphs (Cmax experimental and Tmax 
experimental) and by calculation using the following equations (Eqs. (2) and (3)) (Cmax calculated and Tmax calculated): 
 
Absolute bioavailability (Fabsol) was evaluated using the following relation (Eq. (4)): 
 
Where Doral and DIV are the oral and IV administered drug quantities, respectively. 
All pharmacokinetic parameters were reported as means ± standard deviations except absolute bioavailability, 
calculated from average AUC0-∞· 
Data were regarded as aberrant when the individual AUC value was higher or lower than mean ± 2 standard 
deviations. For this reason, one sheep was excluded from the determination of pharmacokinetic parameters after 
the oral solution administration and from statistical analysis. 
The comparison of pharmacokinetic parameters for the two oral dosage forms was performed with a two-way 
analysis of variance (two-way ANOVA). After log-transformation in order to normalize the distribution, the 
mean values of each calculated parameter were compared. Results were considered to be significant at the 5% 
critical level (p<0.05). 
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3. Results and discussion 
3.1. Solubility studies 
It has already been shown by Bertholet et al. that several CDs (β-CD, -γ-CD and derivatives, such as randomly-
methylated-β-CD (Rameb) and HP-β-CD) are able to form inclusion complexes with Ro 28-2653 and to increase 
its aqueous solubility. The best results were obtained with Rameb and HP-β-CD. A 200mM Rameb or HP-β-CD 
solution, respectively, increased the aqueous solubility of Ro 28-2653 by about 24,000 and 10,000 times at 37°C 
(Bertholet et al., 2005). 
Being safe for intravenous administration, HP-β-CD was chosen for the present study. Fig. 2 shows the phase 
solubility diagram of Ro 28-2653 obtained at 25 °C in the presence of HP-β-CD in purified water, in a 50mM         
L-lysine solution and in a 500 mM L-lysine solution. In the three cases, the aqueous solubility of Ro 28-2653 
increased as a function of CD concentration. The solubility diagram obtained in the absence of L-lysine confirms 
the previously mentioned results: the solubility of Ro 28-2653 in a 200 mM HP-β-CD solution was 
approximately 5.5mg/ml (±11mM), which corresponds to a 10,000 times increase in Ro 28-2653 aqueous 
solubility. 
In the presence of L-lysine, Ro 28-2653 solubility in HP-β-CD solutions was even higher. Solubility in a 200 
mM HP-β-CD solution was increased by about two and seven times in the presence of 50 and 500 mM of L-
lysine, respectively. Table 2 shows solubility data of Ro 28-2653 in the different media and pH values of the 
solutions obtained at equilibrium. Results show a synergistic effect between L-lysine and HP-β-CD. Solubility in 
the presence of both 500 mM L-lysine and 200 mM HP-β-CD (38.14mg/ml) was higher than had been expected 
by adding separately the effect of HP-β-CD and L-lysine (5.53 and 0.09mg/ml). This synergistic effect between 
L-lysine and HP-β-CD allowed a significant increase in Ro 28-2653 aqueous solubility (70,000 times with 500 
mM of L-lysine and 200 mM of HP-β-CD). The Ro 28-2653 solubility increased with L-lysine concentration and 
consequently with pH value. In fact, the increase in Ro 28-2653 aqueous solubility was probably due to 
synergistic effect between cyclodextrin and pH obtained with L-lysine at equilibrium. 
Solutions for the pharmacokinetic studies were developed with a combination of HP-β-CD and L-lysine, 
allowing a high Ro 28-2653 concentration with a biocompatible pH value. Concentrations are given in Section 
2.3 above. 
 
Fig. 2 - Phase solubility diagram of Ro 28-2653 with HP-β-CD in purified water (●), L-lysine 50mM (×) or L-




Table 2 - Solubility of Ro 28-2653 (mg/ml) in purified water and in L-lysine (50 and 500 mM) without or with 
HP-β-CD (200 mM) and pH values of the corresponding solutions 
 Without CD With HP-β-CD (200 mM) 
 Drug solubility (mg/ml) pH value Drug solubility (mg/ml) pH value 
Purified water About 0.56 x 10-3 - 5.53 - 
L-lysine (50 mM) 0.05 9.8 17.08 8.8 
L-lysine (500 mM) 0.09 10.0 38.14 9.8 
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3.2. Pharmacokinetics of Ro 28-2653 after intravenous administration 
The mean Ro 28-2653 serum concentration versus time curve obtained after a single administration of the 
intravenous solution (5mg/kg) to sheep is reported in Fig. 3a. Fig. 3b (logarithm of the mean Ro 28-2653 serum 
concentration versus time curve) shows that Ro 28-2653 pharmacokinetics seem to follow a two-compartment 
model. The different pharmacokinetic parameters calculated after this intravenous administration are listed in 
Table 3. 
The distribution phase was short (about 30min), showing that Ro 28-2653 is rapidly distributed through the 
organism. The overall volume of distribution was small (about 81), indicating that Ro 28-2653 distribution could 
be limited to extracellular fluids and that Ro 28-2653 diffusion into tissues may not be very significant. On the 
other hand, Ro 28-2653 biologic half-life was shown to be long (about 15.5h), with drug elimination 
consequently being very slow. Considering its small distribution volume, accumulation in the organism might 
not be caused by storage, for example, in fat, but possibly through strong binding with proteins or other 
componentsof plasma. The total body clearance value was also calculated at approximately 358.5 ml/h. 
3.3. Pharmacokinetics of Ro 28-2653 after oral administration of a suspension and a solution 
The mean serum concentration versus time profiles of Ro 28-2653 obtained after oral administration of a single 
dose (15 mg/kg) of Ro 28-2653 solution and suspension are shown in Fig. 4a. After logarithmic transformation 
of mean serum concentration, it seemed that the pharmacokinetics after oral administration would follow a one-
compartment model (Fig. 4b). The pharmacokinetic parameters are summarized in Table 4. 
 
Table 3 - Ro 28-2653 pharmacokinetic parameters (mean ± S.D.) obtained after intravenous administration (5 
mg/kg) to sheep (n = 6) 
 IV Solution 
AUC0-168h (µgh/ml) 858.11 ± 211.58 
AUC0-∞ (µgh/ml) 858.87 ± 212.08 
Glt (ml/h) 358.76 ± 67.47 
Vdt (l) 8.18 ± 2.16 
T1/2β (h) 15.76 ± 2.34 
 
 
Fig. 3 - Mean (±S.D.) Ro 28-2653 serum concentration (a) or logarithm of the mean Ro 28-2653 serum 
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Fig. 4 - Mean (±S.D.) Ro 28-2653 serum concentration (a) or logarithm of the mean Ro 28-2653 serum 
concentration (b) vs. time curve after oral administration (15 mg/kg) of a solution (A) and a suspension (·) to 




Table4 – Ro 28-2653 Pharmacokinetic parameters(mean ± S.D., except for F) obtained after oral 
administration (15mg/Kg) to sheep 
 Oral solution (n = 5) Suspension (n = 6) p-Value (n = 5) 
AUC0-168h (µgh/ml) 1848.66 ±854.97 208.94 ±103.82 0.0049 
AUC0-∞ (µgh/ml) 2070.13 ±943.79 214.65 ±103.04 0.0035 
Cmax experimental (µgh/ml) 51.84±23.73 4.84 ±1.95 0.0009 
Cm ax calculated (µg/ml) 56.85 ±24.67 5.34 ±2.24 0.0010 
Tmax experimental (h) 3.59 ±1.52 12.34±5.99 0.0094 
Cmax calculated (h) 3.98 ±0.57 10.42 ±3.01 0.0046 
Fabsol 0.80 0.08 - 
 
The serum concentrations of Ro 28-2653 after administration of the solution were clearly higher than those 
obtained with an equal dose administered as a suspension. The absorption phase observed with the solution 
(about 4h) was shorter than that achieved after administration of the suspension (about 10h). It can also be seen 
that the pharmacokinetic parameters of the solution and the suspension were significantly different (p < 0.05) 
(Table 4). The mean Ro 28-2653 serum peak concentrations were approximately 54 and 5 µg/ml after 
administration of the solution and the suspension, respectively. Cmax of the solution was about 10 times higher 
than that of the suspension. A three times earlier Tmax was obtained with the solution (about 3.8h) than with the 
suspension (about 11h). The AUC values followed the same trend as the Cmax values: the AUCs after 
administration of the solution were about 10 times higher than those after administration of the suspension. 
Consequently, after comparison with the IV solution, absolute bioavailability was much higher with the solution 
(80%) than with the suspension (8%). 
The enhancement of bioavailability was ascribed to the increase in the drug's solubility and was supposed to be 
caused by the same synergistic effect between cyclodex-trin and pH obtained with L-lysine at equilibrium. The 
rapid intestinal absorption of drugs included in a cyclodextrin complex could be explained by the competition 
between the drug and endogenous lipids of the gastro-intestinal tract (Frijlink et al., 1990). Most drugs will be 
released from the complex and become available for absorption because of the abundant availability of those 
endogenous lipids. In view of this increase in absorption and bioavailability, the solution containing cyclodextrin 
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would be a safe and very effective way to achieve acceptable blood levels from a lower dose of Ro 28-2653. 
In addition, although oral administration of a solution often reduces inter and intra individual variability of 
absorption, the standard deviation values of the different pharmacokinetic parameters obtained here were large, 
suggesting an important variability in Ro 28-2653 absorption. This variability may be a problem in determining 
an effective dose for all individuals of a population. 
4. Conclusions 
In this study, it has been shown that a synergistic effect between L-lysine and HP-β-CD allows a significant 
increase in Ro 28-2653 aqueous solubility (70,000 times). The use of this multicomponent system permitted the 
preparation of oral and intravenous solutions of Ro 28-2653. Consequently, intravenous administration of Ro 28-
2653 is possible with less toxic excipients than when using other usual solubilizing agents as, for example, 
surfactants. The oral solution also presents some advantages. Absolute bioavailability of this oral solution of Ro 
28-2653 was significantly higher (about 10 times) than that obtained with a suspension of the same drug. In 
addition, this solution was characterized by a higher Cmax and a lower Tmax. The solubilization of the drug before 
oral administration allowed for rapid and more significant gastrointestinal absorption of Ro 28-2653. 
Moreover, the in vivo administration of Ro 28-2653 solutions highlighted some information about the 
pharmacokinetic behavior of this new drug. Ro 28-2653 was shown to be rapidly distributed in the organism, its 
biologic half-life was long (about 15.5h) and the total volume of distribution very small (about 81). 
These new intravenous and oral solutions open new opportunities to test in vivo efficacy of this new MMP 
inhibitor with regard both to its antitumoral activities and its antiangiogenic properties. 
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